Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Breast 1

Conditions

Sarcoma, Ewing 1Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Bevacizumab 39Paclitaxel 34pembrolizumab 27Carboplatin 26Specimen Handling 21olaparib 19Magnetic Resonance Spectroscopy 19Gemcitabine 18liposomal doxorubicin 16Cyclophosphamide 16niraparib 13fludarabine 12Topotecan 12Biopsy 12Cisplatin 11Taxes 8Nivolumab 8Immunoglobulin G 8Fulvestrant 8Disulfides 8Surveys and Questionnaires 7Doxorubicin 7palbociclib 6aldesleukin 6Oxaliplatin 6Letrozole 5Fluorouracil 5trastuzumab deruxtecan 4oregovomab 4mirvetuximab soravtansine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × romiplostim × 90 days × Clear all
NCT03937154 2026-04-07

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Amgen

Phase 3 Active not recruiting
145 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡